Fludara

(Fludarabine Phosphate)

Phase 3Small molecule

Fludarabine phosphate is used to treat certain blood cancers, particularly chronic lymphocytic leukemia (CLL), by killing cancer cells and weakening the immune system in patients who haven't responded well to other treatments.[1] Fludara is currently being investigated across 67 indications[3], with its most advanced program in Phase 3.[1]

Fludara is one of 1181 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

385

Total Trials

Active Trials

1,180

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

Lymphoplasmacytic LymphomaActive, not recruiting

MacroglobulinemiaActive, not recruiting

Aplastic AnemiaActive, not recruiting

Kidney CancerActive, not recruiting

Prolymphocytic LeukemiaActive, not recruiting

LymphomaActive, not recruiting

Head and Neck Malignant NeoplasiaActive, not recruiting

Cutaneous MelanomaActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Non-Hodgkins LymphomaPhase 2

Active, not recruiting

Lymphoplasmacytic LymphomaPhase 3

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

Aplastic AnemiaPhase 2/Phase 3

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Prolymphocytic LeukemiaPhase 2

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Head and Neck Malignant NeoplasiaPhase 1

Active, not recruiting

Cutaneous MelanomaPhase 2

Active, not recruiting

Showing 10 of 67 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

5 2

Avastin

Voltaren

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Chronic Lymphocytic Leukemia

NCT02153580

Q4 2026

Phase 1Recruiting

Melanoma

NCT04119024

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Q1 2027

Phase 1Active, not recruiting

Mantle Cell Lymphoma

NCT05495464

Q2 2027

Phase 1/2Active, not recruiting

Graft Versus Host Disease

NCT03192397

Clinical

Trials by Indication[1]

Stem Cell Transplant23 trials

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT01300572·16 enrolled

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00075478·87 enrolled

Show 20 more trials

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Completed·NNorthside Hospital, Inc.·Phase 2·NCT00787761·24 enrolled

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Completed·UUniversity of California, San Francisco·N/A·NCT00296023·25 enrolled

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting·UUniversity of Chicago·Phase 1·NCT02333162·30 enrolled

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04776850

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No longer available·BBarbara Ann Karmanos Cancer Institute··NCT00423826

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027560·51 enrolled

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01056614·23 enrolled

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00346359·40 enrolled

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00392782·24 enrolled

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT00818961·36 enrolled

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00303667·50 enrolled

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00112567·20 enrolled

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Unknown status·IInstitut Paoli-Calmettes·Phase 2·NCT00740467·50 enrolled

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00448201·71 enrolled

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Completed·—·Phase 1·NCT00376480·19 enrolled

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Completed·—·Phase 2·NCT00627666·52 enrolled

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01823198·63 enrolled

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00118352·12 enrolled

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Completed·UUniversity of California, San Francisco·Phase 2·NCT00301834·35 enrolled

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00255710·60 enrolled

Chronic Lymphocytic Leukemia18 trials

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

Completed·VVirginia Commonwealth University·Phase 1·NCT00005580·54 enrolled

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004857·86 enrolled

Show 15 more trials

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003764·280 enrolled

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT00045513

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04007029·24 enrolled

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00104858·66 enrolled

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00425802·61 enrolled

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00275015·169 enrolled

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00098670·102 enrolled

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Active, not recruiting·—·Phase 1·NCT02153580·37 enrolled

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017108

Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003248·104 enrolled

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00513747·84 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Completed·CCancer Research UK·Phase 2·NCT00337246·56 enrolled

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00068315·18 enrolled

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Completed· Sanofi logo

Sanofi·Phase 4·NCT00220311·10 enrolled

Acute Myeloid Leukemia13 trials

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT02791919

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00101140

Show 10 more trials

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00005863

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Suspended·SSt. Jude Children's Research Hospital·Phase 2·NCT05955261·70 enrolled

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00070135·121 enrolled

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00045435·17 enrolled

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Completed·—·Phase 2·NCT01020734·263 enrolled

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06871410·26 enrolled

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1/2·NCT02642965·38 enrolled

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·NNohla Therapeutics, Inc.·Phase 1·NCT01701323·7 enrolled

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01707004·20 enrolled

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·NNorthwestern University·Phase 1·NCT04250051·2 enrolled

Metastatic Melanoma10 trials

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02500576·18 enrolled

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00079144

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·—·Phase 2·NCT00085423·20 enrolled

Show 7 more trials

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00096382·34 enrolled

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303836·58 enrolled

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01807182·11 enrolled

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01740557·10 enrolled

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Completed·PProf. Serge Leyvraz·Phase 1·NCT00324623·8 enrolled

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT00062036·33 enrolled

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00138229·6 enrolled

Lymphoma9 trials

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00110071·38 enrolled

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00079443·60 enrolled

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00006100

Show 6 more trials

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT04074746·45 enrolled

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Completed·—·Phase 1·NCT00182650·5 enrolled

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00119392·42 enrolled

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Withdrawn·NNational Institutes of Health Clinical Center (CC)·N/A·NCT00389506

S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00121186·1 enrolled

Fludara (Oral) Phase II Study for Indolent Lymphoma

Completed· Sanofi logo

Sanofi·Phase 2·NCT00688883·52 enrolled

66 more indications

Kidney Cancer7 trials

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00027573·36 enrolled

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262886·35 enrolled

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00078858·37 enrolled

Show 4 more trials

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00005799·55 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Withdrawn·NNorthwestern University·Phase 1·NCT00006126

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004135·19 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Withdrawn·FFox Chase Cancer Center·Phase 2·NCT00025519

Hematologic Cancer6 trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00723099·73 enrolled

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00009984·70 enrolled

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Terminated·UUniversity of Rochester·N/A·NCT00255684·16 enrolled

Show 3 more trials

Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290641·68 enrolled

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00301951·7 enrolled

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00963872·31 enrolled

Hematologic Malignancies6 trials

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·RRoswell Park Cancer Institute·Phase 2·NCT01529827·94 enrolled

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Withdrawn·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT01652014

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01760655·62 enrolled

Show 3 more trials

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00343798·23 enrolled

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT06343376·1 enrolled

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02960646·11 enrolled

Multiple Myeloma6 trials

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06066359·44 enrolled

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006184·20 enrolled

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Not yet recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT04579523·30 enrolled

Show 3 more trials

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Completed·—·Phase 1·NCT01163357·18 enrolled

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Terminated·—·Phase 1·NCT01954784·8 enrolled

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00028600·60 enrolled

Graft Versus Host Disease5 trials

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Completed·—·Phase 2·NCT00589563·32 enrolled

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT01231412·174 enrolled

Show 2 more trials

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01251575·77 enrolled

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT03192397·35 enrolled

Myelodysplastic Syndrome5 trials

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01168219·68 enrolled

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00077558

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00801489·270 enrolled

Show 2 more trials

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00322101·25 enrolled

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Unknown status·FFred Hutchinson Cancer Center·Phase 2·NCT01894477·102 enrolled

Acute Lymphoblastic Leukemia5 trials

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00589316·26 enrolled

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00988715·17 enrolled

Show 2 more trials

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00027547

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Withdrawn·JJuventas Cell Therapy Ltd.·Phase 1/2·NCT06009107

Leukemia5 trials

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 3·NCT00281918·817 enrolled

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005802

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00066417·51 enrolled

Show 2 more trials

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Withdrawn·CChildren's Oncology Group·Phase 1/2·NCT05320380

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Chronic Myelogenous Leukemia4 trials

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT01640301·47 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027924

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002833·53 enrolled

Show 1 more trial

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00305708·40 enrolled

Melanoma3 trials

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006233

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Recruiting·AAnusha Kalbasi·Phase 1·NCT04119024·18 enrolled

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00610311·3 enrolled

Myelofibrosis3 trials

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03426969·3 enrolled

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Withdrawn·—·Phase 1·NCT02528877

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Completed·—·Phase 1·NCT02917096·18 enrolled

Mantle Cell Lymphoma3 trials

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00058227·37 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT00053092·82 enrolled

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05495464·22 enrolled

Bone Marrow Transplant3 trials

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134004·210 enrolled

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00028730·25 enrolled

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00049504·53 enrolled

Breast Cancer3 trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Terminated·UUniversity of California, San Diego·Phase 2·NCT00074269·5 enrolled

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00365287·148 enrolled

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020176

Renal Cell Carcinoma2 trials

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Completed·—·N/A·NCT00073879

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT05703854·50 enrolled

Colorectal Cancer2 trials

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06358430·42 enrolled

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT05040568·15 enrolled

Stem Cell Transplantation2 trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT00004114

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004145·16 enrolled

Hematological Diseases2 trials

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00309842·213 enrolled

Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

Completed·WWake Forest University Health Sciences·Phase 2·NCT02248597·27 enrolled

Bone Marrow Transplantation2 trials

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Completed·UUnknown Sponsor·Phase 2/3·NCT00004255

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00006042

Hematological Malignancies2 trials

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00040846·60 enrolled

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01527045·47 enrolled

Prevention2 trials

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00914940·41 enrolled

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Recruiting·MMarcela V. Maus, M.D.,Ph.D.·Phase 2·NCT06550141·28 enrolled

Myelodysplastic Syndromes2 trials

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008177·79 enrolled

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Cancer2 trials

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

Terminated·CCancer Research UK·Phase 1·NCT01212887·14 enrolled

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00796068·130 enrolled

Stem Cell2 trials

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01858740·20 enrolled

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02220985·84 enrolled

Recurrent or Refractory1 trial

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting·SStanford University·Phase 1·NCT03233854·56 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled

Lymphoplasmacytic Lymphoma1 trial

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Completed·—·Phase 3·NCT00608374·400 enrolled

Metastatic Cancer1 trial

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00704938·3 enrolled

Brain Cancer1 trial

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04521946

Myeloid Malignancies1 trial

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06383572·44 enrolled

Follicular Lymphoma1 trial

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06043323·20 enrolled

Immunotherapy1 trial

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01145209·32 enrolled

Blood Disease1 trial

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled

Prostate Cancer1 trial

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·—·Phase 1·NCT03873805·14 enrolled

Advanced1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00719849·13 enrolled

Donor1 trial

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT01598025·3 enrolled

Bone Marrow Failure Syndrome1 trial

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Completed·UUniversity of California, San Francisco·Phase 1·NCT00295971·21 enrolled

Relapsed or Refractory1 trial

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00871689·2 enrolled

Lymphoid Malignancies1 trial

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02529813·26 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06066424·54 enrolled

Systemic Sclerosis1 trial

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00622895·3 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Completed·—·Phase 1·NCT01658319·20 enrolled

AIN1 trial

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06083883·44 enrolled

Hematologic Disease1 trial

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00376519·3 enrolled

Acute Graft Versus Host Disease1 trial

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00105001·210 enrolled

B-cell NHL1 trial

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Completed·—·Phase 2·NCT00577278·41 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT01824693·30 enrolled

Efficacy1 trial

A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT00565981·10 enrolled

Allogeneic Stem Cell Transplantation1 trial

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Completed·—·N/A·NCT00068523·10 enrolled

Macroglobulinemia1 trial

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00020800·7 enrolled

Bone Marrow Failure Disorders1 trial

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Completed·RRoswell Park Cancer Institute·N/A·NCT00856388·62 enrolled

Autoimmune Disorders1 trial

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06434363·47 enrolled

Frontline1 trial

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00794820·66 enrolled

Acute Leukemia1 trial

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02083250·70 enrolled

Severe Aplastic Anemia1 trial

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Completed·—·Phase 1·NCT00054236·55 enrolled

Immunodeficiency1 trial

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00358657·14 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

Completed· Sanofi logo

Sanofi·Phase 2·NCT00185445·62 enrolled

Myeloid Neoplasm1 trial

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Completed·GGeoVax, Inc.·Phase 1/2·NCT03754933·10 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Withdrawn·NNationwide Children's Hospital·Phase 2·NCT00874315

Diffuse Large B-Cell Lymphoma1 trial

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting·MMehrdad Abedi, MD·Phase 1·NCT05052528·36 enrolled

Unspecified2 trials

Intra-Osseous Co-Transplant of UCB and hMSC

Completed·—·Phase 1·NCT02181478·6 enrolled

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Terminated·—·Phase 1·NCT02774291·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 385 trial records for Fludarabine Phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine Phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine Phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Fludara

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Stem Cell Transplant23 trials

Chronic Lymphocytic Leukemia18 trials

Acute Myeloid Leukemia13 trials

Metastatic Melanoma10 trials

Lymphoma9 trials

Kidney Cancer7 trials

Hematologic Cancer6 trials

Hematologic Malignancies6 trials

Multiple Myeloma6 trials

Graft Versus Host Disease5 trials

Myelodysplastic Syndrome5 trials

Acute Lymphoblastic Leukemia5 trials

Leukemia5 trials

Chronic Myelogenous Leukemia4 trials

Melanoma3 trials

Myelofibrosis3 trials

Mantle Cell Lymphoma3 trials

Bone Marrow Transplant3 trials

Breast Cancer3 trials

Renal Cell Carcinoma2 trials

Colorectal Cancer2 trials

Stem Cell Transplantation2 trials

Hematological Diseases2 trials

Bone Marrow Transplantation2 trials

Hematological Malignancies2 trials

Prevention2 trials

Myelodysplastic Syndromes2 trials

Cancer2 trials

Stem Cell2 trials

Recurrent or Refractory1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Lymphoplasmacytic Lymphoma1 trial

Metastatic Cancer1 trial

Brain Cancer1 trial

Myeloid Malignancies1 trial

Follicular Lymphoma1 trial

Immunotherapy1 trial

Blood Disease1 trial

Prostate Cancer1 trial

Advanced1 trial

Donor1 trial

Bone Marrow Failure Syndrome1 trial

Relapsed or Refractory1 trial

Lymphoid Malignancies1 trial

Genetic Disorder1 trial

AML1 trial

Epidermolysis Bullosa1 trial

Patients With Advanced Solid Tumors1 trial

Systemic Sclerosis1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

AIN1 trial

Hematologic Disease1 trial

Acute Graft Versus Host Disease1 trial

B-cell NHL1 trial

Juvenile Myelomonocytic Leukemia1 trial

Efficacy1 trial

Allogeneic Stem Cell Transplantation1 trial

Macroglobulinemia1 trial

Bone Marrow Failure Disorders1 trial

Autoimmune Disorders1 trial

Frontline1 trial

Acute Leukemia1 trial

Severe Aplastic Anemia1 trial

Immunodeficiency1 trial

Efficacy and Safety1 trial

Myeloid Neoplasm1 trial

Hematopoietic Stem Cell Transplant1 trial

Safety and Efficacy1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Diffuse Large B-Cell Lymphoma1 trial

Unspecified2 trials